Experiences with

Elbasvir / Grazoprevir

"Overall, 92.4% of patients achieved SVR12 with 12 weeks of elbasvir/grazoprevir, and 94.2% of patients achieved SVR12 with 12 weeks of elbasvir/grazoprevir plus ribavirin." http://bit.ly/2jA3VFm

"Overall, 92.4% of patients achieved SVR12 with 12 weeks of elbasvir/grazoprevir, and 94.2% of patients achieved SVR12 with 12 weeks of elbasvir/grazoprevir plus ribavirin." http://bit.ly/2jA3VFm

People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a ... http://bit.ly/2cJwETM

https://www.hepmag.com/article/fda-oks-mercks-zepatier-grazoprevirelbasvir-treat-hepatitis-c?utm_source=phplist69&utm_medium=email&utm_content=HTML&utm_campaign=FDA+OKs+Zepatier+%28Grazoprevir%2FElbasvir%29+to+Treat+Hep+C+

http://www.natap.org/2015/AASLD/AASLD_18.htm

http://www.healio.com/hepatology/hepatitis-c/news/online/%7Bb9f3c1c8-ee0a-4a84-a91f-7656272ee5d8%7D/c-edge-grazoprevirelbasvir-benefits-hivhcv-coinfected-patients?utm_source=maestro&utm_medium=email&utm_campaign=hepatology%20news

http://hivandhepatitis.org/hcv-treatment/experimental-hcv-drugs/5474-aasld-2015-grazoprevirelbasvir-shows-high-cure-rate-for-people-who-inject-drugs

http://hepatitiscnewdrugs.blogspot.com/2015/10/merck-to-present-new-data-on-hcv.html

Earlier this week the company said that the FDA had accepted an NDA for grazoprevir/elbasvir, an investigational daily single-tablet combination therapy for hepatitis C. The regulator is expected to decide on the drug by Jan. 28.

Merck’s application is based in part on data from the C-EDGE, C-SURFER and C-SALVAGE clinical trials, which studied grazoprevir/elbasvir with and without ribavirin.

Merck’s application is based in part on data from the C-EDGE, C-SURFER and C-SALVAGE clinical trials, which studied grazoprevir/elbasvir with and without ribavirin.

Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1

Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver Congress™ 2015 http://hepatitiscresearchandnewsupdates.blogspot.com/2015/04/merck-announces-presentation-of-phase-2.html

Twelve weeks of Merck’s grazoprevir and elbasvir, plus ribavirin, cured nearly all treatment-experienced people with genotype 1 of hepatitis C virus (HCV) in a small trial, including those with cirrhosis.